oncology Archives - Page 2 of 10

SalubrisBio’s JK06 shows early promise, but can 5T4 ADCs move beyond niche excitement?

Find out how SalubrisBio’s JK06 data could reshape 5T4-targeted ADC development in lung and breast cancer.

Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.

Pfizer’s $10.5bn Innovent alliance deepens its oncology reset. Can early ADC and multispecific bets become global cancer drugs?

Antengene’s ATG-022 enters pivotal testing in gastric cancer, testing whether CLDN18.2 ADCs can stand out in a crowded oncology field.

Find out how AbbVie’s DECNUPAZ approval could change BPDCN treatment while raising new safety and adoption questions.

Find out how Brenus Pharma’s STC-1010 FDA IND acceptance could reshape MSS colorectal cancer immunotherapy development.

Macrophage cell therapy has promise but painful execution risk. United Immunity’s Carisma deal tests whether in vivo CAR-M can scale.

Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.

Bladder cancer drugs face a value test. ImmunityBio’s ANKTIVA analysis raises new questions on cost, response durability and access.

Gilead’s Trodelvy may move earlier in metastatic TNBC. The EU signal could reshape first-line ADC use, but adoption questions remain.